hotspot -WSS

hotspot

author：comprehensive 2025-10-02 00:18:53 - browse：622

ADAM FEUERSTEIN/STAT

CHICAGO — Corbus Pharmaceuticals is the second best-performing biotech stock this year, thanks to investor interest in an antibody-drug conjugate candidate, or ADC, called CRB-701 with the potential to be better tolerated than Padcev, an ADC treatment bladder cancer that Pfizer acquired as part of its $43 billion Seagen deal.

On Saturday, Corbus updated results from an early, dose-finding study of CRB-701, showing an overall response rate of 28% from 25 evaluable patients. Closer attention is being paid to the subset of 15 patients treated at three therapeutically active doses, where the overall response rate (all partial tumor shrinkage) was 40%. All of the responses were seen in bladder cancer (where Padcev is approved) and in cervical cancer.

The data, from a study conducted in China, were presented in a poster session at the annual meeting of the American Society of Clinical Oncology.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Meta looks to target Twitter with a rival app called Threads

focus

WSS

Zyn nicotine pouches become unlikely player in latest culture war

Did the public have the right to know Arthur Ashe had AIDS?

New clues to why women have higher risk of autoimmune disorders

These geoengineering technologies could help combat the climate crisis, scientists say

Doctor appointment wait times are getting worse

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

leisure time

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

DIEP, the 'gold standard' of breast reconstruction, is under threat

Why Medicare shouldn’t cover every FDA

Activists slam private health insurers over coverage restrictions

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Affirmative action in medical school literally saved lives

Inside the fall of star MIT scientist David Sabatini

State Dept. review finds Biden bears some blame for Afghanistan failures

Doctor appointment wait times are getting worse

At least 13 dead in Texas as scorching temps continue

How generative AI ratchets up security threats for health systems

knowledge

Humana’s losses in Medicare Advantage tank its stock

Ukraine, Russia accuse each other of planning to attack Europe's biggest nuclear plant

Health Care Service Corp to buy Cigna Medicare Advantage plans

Merck, Johnson & Johnson CEOs will testify on high drug prices

Investment in vaccine development is lagging, report finds

Humana’s losses in Medicare Advantage tank its stock

focus

hotspot

focus

explore